跳至主要内容
临床试验/IRCT20220424054645N1
IRCT20220424054645N1尚未招募3 期

Evaluation the efficacy of Livergol(Sylimarin extract) on liver function of thalassemia major and intermedia patients: A triple-blinded, randomized, placebo-controlled trial

Bandare-abbas University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
1 year 至 18 years(—)
性别
All

入选标准

  • Confirmed thalassemia major and intermedia cases with CBC and HB electerophoresis
  • Patients without anaphylactoid reactions to any medication
  • Patients with ALT rising more than two times of upper normal limit
  • Consent to participate in trial
  • Iron overload(serum ferritin of1000-5000ng/l) during 6 months before study
  • Negative CRP

排除标准

  • Hepatitis B or C virus infection
  • HIV positive test
  • Chronic kidney disease
  • Thalassemia major patients with irreversible cirrhosis including 1-hyperglycemia 2-hyperalbuminemia 3-coagulopathy (INR> 1.5 and platelets <15000)
  • Symptoms of increased portal vein pressure include ascites, esophageal varices, splenomegaly
  • Research units have not tendency to continue the study

研究者

发起方
Bandare-abbas University of Medical Sciences

相似试验